FDA removes partial clinical hold on Karyopharm's selinexor studies

|About: Karyopharm Therapeutic... (KPTI)|By:, SA News Editor

Karyopharm Therapeutics (NASDAQ:KPTI) reports that the FDA has lifted the partial clinical hold on clinical trials of lead product candidate selinexor. The partial hold, which stops patient recruitment, was instituted on March 10 due to incomplete information in the existing version of the investigator's brochure, including an incomplete list of selinexor-related serious adverse events.